MEP3208A - Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama - Google Patents
Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinamaInfo
- Publication number
- MEP3208A MEP3208A MEP-32/08A MEP3208A MEP3208A ME P3208 A MEP3208 A ME P3208A ME P3208 A MEP3208 A ME P3208A ME P3208 A MEP3208 A ME P3208A
- Authority
- ME
- Montenegro
- Prior art keywords
- modified
- polypeptides
- pharmacokinetic properties
- chimeric polypeptides
- modified chimeric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13813399P | 1999-06-08 | 1999-06-08 | |
PCT/US2000/014142 WO2000075319A1 (fr) | 1999-06-08 | 2000-05-23 | Polypeptides chimeriques modifies a pharmacocinetique amelioree |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP3208A true MEP3208A (xx) | 2010-02-10 |
Family
ID=22480568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2008-32A ME00024B (fr) | 1999-06-08 | 2000-05-23 | Polypeptides chimeriques modifies a pharmacocinetique amelioree |
MEP-32/08A MEP3208A (xx) | 1999-06-08 | 2000-05-23 | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2008-32A ME00024B (fr) | 1999-06-08 | 2000-05-23 | Polypeptides chimeriques modifies a pharmacocinetique amelioree |
Country Status (33)
Country | Link |
---|---|
EP (2) | EP1544299B1 (fr) |
JP (2) | JP4723140B2 (fr) |
KR (1) | KR100659477B1 (fr) |
CN (3) | CN101433715B (fr) |
AT (2) | ATE417928T1 (fr) |
AU (2) | AU779303B2 (fr) |
BE (1) | BE2013C029I2 (fr) |
BR (2) | BRPI0011407B8 (fr) |
CA (1) | CA2376379C (fr) |
CY (2) | CY1108883T1 (fr) |
CZ (2) | CZ303656B6 (fr) |
DE (2) | DE60019415T2 (fr) |
DK (2) | DK1544299T3 (fr) |
ES (2) | ES2319305T3 (fr) |
FR (1) | FR13C0028I2 (fr) |
HK (3) | HK1043388A1 (fr) |
HR (1) | HRP20010908B1 (fr) |
HU (3) | HU229156B1 (fr) |
IL (3) | IL146890A0 (fr) |
LT (1) | LTC1183353I2 (fr) |
LU (1) | LU92195I2 (fr) |
ME (2) | ME00024B (fr) |
MX (1) | MXPA01012630A (fr) |
NO (3) | NO330775B1 (fr) |
NZ (1) | NZ515913A (fr) |
PL (1) | PL208247B1 (fr) |
PT (2) | PT1183353E (fr) |
RS (1) | RS50073B (fr) |
RU (1) | RU2265661C2 (fr) |
SK (1) | SK287332B6 (fr) |
UA (1) | UA74146C2 (fr) |
WO (1) | WO2000075319A1 (fr) |
ZA (1) | ZA200110068B (fr) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710174B2 (en) | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
EP1353952B1 (fr) | 1994-11-14 | 2007-04-11 | Ludwig Institute For Cancer Research | Flt4 (vegfr-3) utilise comme cible pour l'imagerie des tumeurs et le traitement antitumoral |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US6734017B2 (en) | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
AU2003304173A1 (en) | 2002-05-04 | 2005-01-04 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
CA2519787C (fr) | 2003-03-28 | 2012-06-05 | Regeneron Pharmaceuticals, Inc. | Methodes de traitement du diabete par blocage de l'activite induite par le facteur de croissance endotheliale |
WO2004110360A2 (fr) | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
EP1646353A4 (fr) * | 2003-05-16 | 2008-06-04 | Acorda Therapeutics Inc | Proteines de fusion destinees au traitement du systeme nerveux central |
EP1626989A2 (fr) | 2003-05-28 | 2006-02-22 | Regeneron Pharmaceuticals, Inc. | Methode de traitement du rejet de greffon corneen utilisant des antagonistes du facteur de croissance de l'endothelium vasculaire (vegf) |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
CA2519875C (fr) * | 2003-06-06 | 2014-01-14 | Regeneron Pharmaceuticals, Inc. | Methode favorisant la regression de tumeurs au moyen d'inhibiteurs du vegf (facteur de croissance de l'endothelium vasculaire) |
US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
US20050112061A1 (en) * | 2003-08-06 | 2005-05-26 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
JP4926962B2 (ja) | 2004-05-18 | 2012-05-09 | アコーダ セラピューティクス、インク. | コンドロイチン分解酵素とその安定な製剤の精製法 |
JP4680997B2 (ja) * | 2004-06-08 | 2011-05-11 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管新生を阻害するキメラタンパク質およびその利用 |
CA2567686A1 (fr) * | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Methode d'administration et d'utilisation d'inhibiteurs de vegf pour le traitement d'un cancer humain |
AU2005265071A1 (en) * | 2004-06-18 | 2006-01-26 | Memorial Sloan-Kettering Cancer Center | VEGF inhibitors for the treatment of malignant pleural effusion |
CN1997386B (zh) * | 2004-07-30 | 2012-05-30 | 瑞泽恩制药公司 | 通过阻断vegf介导的活性来治疗i型糖尿病的方法 |
EP1804835B9 (fr) | 2004-09-13 | 2010-09-29 | Genzyme Corporation | Constructions multimeriques |
FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
CN101141975B (zh) | 2005-03-25 | 2012-05-23 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
ES2393748T3 (es) | 2005-09-26 | 2012-12-27 | Acorda Therapeutics, Inc. | Composiciones y métodos de uso de condroitinasa ABCI mutantes |
PL1962895T3 (pl) † | 2005-12-16 | 2013-06-28 | Regeneron Pharma | Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów |
FR2895258B1 (fr) | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
CN100502945C (zh) * | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 vegf 길항제 제형 |
EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
WO2008045970A2 (fr) | 2006-10-10 | 2008-04-17 | Acorda Therapeutics, Inc. | Compositions et procédés d'utilisation de mutants des chondroïtinases abci |
FR2918279B1 (fr) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
CN101575379B (zh) * | 2008-05-09 | 2012-05-30 | 上海抗体药物国家工程研究中心有限公司 | 可溶性vegfr双功能融合受体、其制备方法及用途 |
KR101698362B1 (ko) | 2008-11-03 | 2017-01-20 | 몰리큘라 파트너스 아게 | Vegf-a 수용체 상호작용을 억제하는 결합 단백질 |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
TWI510246B (zh) * | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
SI2601214T1 (en) | 2010-08-06 | 2018-03-30 | Genzyme Corporation | VEGF antagonist compositions and their use |
JP6043629B2 (ja) * | 2011-01-07 | 2016-12-14 | 中外製薬株式会社 | 抗体の物性を改善させる方法 |
KR20210030510A (ko) | 2011-01-13 | 2021-03-17 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
CA2857168C (fr) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | Inhibiteurs proteiques du complement et des voies du vegf, et procedes d'utilisation associes |
CN103304668B (zh) * | 2012-03-12 | 2015-10-28 | 江苏健德生物药业有限公司 | Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用 |
US10568934B2 (en) | 2012-05-07 | 2020-02-25 | Allergan, Inc. | Method of treating AMD in patients refractory to anti-VEGF therapy |
WO2014006113A1 (fr) | 2012-07-03 | 2014-01-09 | Sanofi | Procédé de traitement du cancer par quantités efficaces d'aflibercept |
AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
EP3693381A1 (fr) | 2013-02-18 | 2020-08-12 | Vegenics Pty Limited | Molécules de liaison à des ligands et utilisations de celles-ci |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
CN104193828B (zh) * | 2013-09-12 | 2017-04-05 | 北京韩美药品有限公司 | 同时阻断her2和vegfr信号通路的重组融合蛋白 |
KR20160070164A (ko) | 2013-11-05 | 2016-06-17 | 알러간, 인코포레이티드 | 항-vegf darpin으로 눈의 병태를 치료하는 방법 |
EP3143044A1 (fr) | 2014-05-12 | 2017-03-22 | Formycon AG | Seringue en plastique préremplie contenant un antagoniste de vegf |
EP3170005B1 (fr) | 2014-07-18 | 2019-04-10 | Sanofi | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
WO2016094673A1 (fr) | 2014-12-11 | 2016-06-16 | Bayer Healthcare Llc | Traitement d'une dégénérescence maculaire liée à l'âge accompagnée d'une petite lésion de néovascularisation choroïdienne active |
GB201503453D0 (en) | 2015-03-01 | 2015-04-15 | Jain Arjun | Endothelin-1"sponge" |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
WO2017046140A1 (fr) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne |
KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
WO2017065559A1 (fr) | 2015-10-15 | 2017-04-20 | (주)알테오젠 | Procédé de production de protéine de fusion présentant un domaine fc d'igg |
US11654046B2 (en) | 2015-11-18 | 2023-05-23 | Sio2 Medical Products, Inc. | Pharmaceutical package for ophthalmic formulations |
WO2018218013A2 (fr) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Conditionnement pharmaceutique stérilisable pour formulations ophtalmiques |
MX2018006092A (es) | 2015-11-18 | 2019-01-31 | Formycon Ag | Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf. |
BR112018010005A2 (pt) | 2015-11-18 | 2018-11-21 | Formycon Ag | seringa pré-carregada, e, kit |
WO2017084616A1 (fr) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Méthodes et compositions de liaison de vegf |
HRP20231379T1 (hr) | 2015-12-03 | 2024-02-16 | Regeneron Pharmaceuticals, Inc. | Postupci dovođenja u vezu genskih varijanti s kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije liječenih anti-vegf-om |
US10576128B2 (en) | 2016-01-26 | 2020-03-03 | Formycon Ag | Liquid formulation of a VEGF antagonist |
US20190300607A1 (en) | 2016-10-12 | 2019-10-03 | Daiichi Sankyo Company, Limited | Composition containing anti-robo4 antibody and other agents |
CN109937034B (zh) | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
WO2018217995A1 (fr) | 2017-05-24 | 2018-11-29 | Formycon Ag | Conditionnements pharmaceutiques pré-remplis stérilisables comprenant une formulation liquide d'un antagoniste du vegf |
WO2018215580A1 (fr) | 2017-05-24 | 2018-11-29 | Formycon Ag | Procédé de stérilisation de seringues en plastique pré-remplies contenant un antagoniste du vegf |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
WO2019020777A1 (fr) | 2017-07-26 | 2019-01-31 | Formycon Ag | Formulation liquide d'un antagoniste du vegf |
EP3668985B1 (fr) | 2017-08-17 | 2021-06-16 | Just-Evotec Biologics, Inc. | Procédé de purification de protéine glycosylée à partir de galectines et d'autres contaminants de cellules hôtes |
CN111356471A (zh) | 2017-11-20 | 2020-06-30 | 济世发展生物药业有限公司 | 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途 |
CN111770999A (zh) | 2017-11-27 | 2020-10-13 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和用于抑制血管生成的应用 |
IL274711B1 (en) | 2017-11-30 | 2024-06-01 | Regeneron Pharma | Use of VEGF antagonist to treat angiogenic eye disorders |
AU2018385394B2 (en) * | 2017-12-13 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Devices and systems for chromatography column bed support management and related methods |
WO2019147944A1 (fr) * | 2018-01-26 | 2019-08-01 | The Regents Of The University Of California | Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf |
EP4364724A2 (fr) | 2018-05-10 | 2024-05-08 | Regeneron Pharmaceuticals, Inc. | Formulations contenant une protéine de fusion à haute concentration du récepteur vegf |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
CN111378044B (zh) | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
EP3969564A1 (fr) | 2019-05-16 | 2022-03-23 | Formycon AG | Procédé de réduction de l'oxydation de la méthionine dans des protéines recombinantes |
WO2021046070A1 (fr) | 2019-09-03 | 2021-03-11 | Amgen Inc. | Dispositif d'injection destiné à l'administration de médicament et emballage destiné au dispositif d'injection |
US20210077645A1 (en) | 2019-09-16 | 2021-03-18 | Amgen Inc. | Method for external sterilization of drug delivery device |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
BR112022010686A2 (pt) | 2019-12-06 | 2022-08-23 | Regeneron Pharma | Mini-traps de vegf e métodos de uso dos mesmos |
IL302538A (en) * | 2019-12-06 | 2023-07-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
US20210261297A1 (en) | 2020-02-24 | 2021-08-26 | Amgen, Inc. | Containers and systems for use during external sterilization of drug delivery devices |
EP4145456A1 (fr) | 2021-09-06 | 2023-03-08 | Bayer AG | Prédiction d'un changement relatif à un fluide maculaire |
WO2023092324A1 (fr) | 2021-11-24 | 2023-06-01 | 苏州光度生物科技有限公司 | Molécule de liaison de ligand multispécifique et son utilisation |
KR20240019034A (ko) * | 2022-08-02 | 2024-02-14 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
-
2000
- 2000-05-23 ES ES05001328T patent/ES2319305T3/es not_active Expired - Lifetime
- 2000-05-23 CZ CZ20100386A patent/CZ303656B6/cs not_active IP Right Cessation
- 2000-05-23 EP EP05001328A patent/EP1544299B1/fr not_active Expired - Lifetime
- 2000-05-23 PT PT00932721T patent/PT1183353E/pt unknown
- 2000-05-23 RU RU2002100071/13A patent/RU2265661C2/ru active Protection Beyond IP Right Term
- 2000-05-23 KR KR1020017015839A patent/KR100659477B1/ko active Protection Beyond IP Right Term
- 2000-05-23 CN CN2008101093559A patent/CN101433715B/zh not_active Expired - Lifetime
- 2000-05-23 IL IL14689000A patent/IL146890A0/xx unknown
- 2000-05-23 CA CA002376379A patent/CA2376379C/fr not_active Expired - Lifetime
- 2000-05-23 EP EP00932721A patent/EP1183353B1/fr not_active Expired - Lifetime
- 2000-05-23 DE DE60019415T patent/DE60019415T2/de not_active Expired - Lifetime
- 2000-05-23 MX MXPA01012630A patent/MXPA01012630A/es active IP Right Grant
- 2000-05-23 DK DK05001328T patent/DK1544299T3/da active
- 2000-05-23 JP JP2001502582A patent/JP4723140B2/ja not_active Expired - Lifetime
- 2000-05-23 BR BRPI0011407A patent/BRPI0011407B8/pt unknown
- 2000-05-23 BR BR0011407-3A patent/BR0011407A/pt not_active IP Right Cessation
- 2000-05-23 PT PT05001328T patent/PT1544299E/pt unknown
- 2000-05-23 AT AT05001328T patent/ATE417928T1/de active
- 2000-05-23 ES ES00932721T patent/ES2237429T3/es not_active Expired - Lifetime
- 2000-05-23 CZ CZ20014387A patent/CZ302689B6/cs unknown
- 2000-05-23 PL PL352246A patent/PL208247B1/pl active Protection Beyond IP Right Term
- 2000-05-23 AU AU50404/00A patent/AU779303B2/en active Active
- 2000-05-23 SK SK1752-2001A patent/SK287332B6/sk not_active IP Right Cessation
- 2000-05-23 CN CN201310118971.1A patent/CN103349781B/zh not_active Expired - Lifetime
- 2000-05-23 WO PCT/US2000/014142 patent/WO2000075319A1/fr active Application Filing
- 2000-05-23 RS YUP-869/01A patent/RS50073B/sr unknown
- 2000-05-23 HU HU0201515A patent/HU229156B1/hu active Protection Beyond IP Right Term
- 2000-05-23 AT AT00932721T patent/ATE293164T1/de active
- 2000-05-23 DK DK00932721T patent/DK1183353T3/da active
- 2000-05-23 ME MEP-2008-32A patent/ME00024B/fr unknown
- 2000-05-23 UA UA2001128378A patent/UA74146C2/uk unknown
- 2000-05-23 CN CNB008115443A patent/CN100523187C/zh not_active Expired - Lifetime
- 2000-05-23 NZ NZ515913A patent/NZ515913A/xx not_active IP Right Cessation
- 2000-05-23 ME MEP-32/08A patent/MEP3208A/xx unknown
- 2000-05-23 DE DE60041159T patent/DE60041159D1/de not_active Expired - Lifetime
- 2000-05-23 HU HU1300086A patent/HU230159B1/hu unknown
-
2001
- 2001-12-03 IL IL146890A patent/IL146890A/en active Protection Beyond IP Right Term
- 2001-12-06 ZA ZA200110068A patent/ZA200110068B/xx unknown
- 2001-12-07 HR HR20010908A patent/HRP20010908B1/xx not_active IP Right Cessation
- 2001-12-10 NO NO20016036A patent/NO330775B1/no active Protection Beyond IP Right Term
-
2002
- 2002-07-04 HK HK02105009A patent/HK1043388A1/xx not_active IP Right Cessation
-
2005
- 2005-03-31 AU AU2005201365A patent/AU2005201365B2/en not_active Expired
-
2008
- 2008-03-17 IL IL190234A patent/IL190234A0/en not_active IP Right Cessation
-
2009
- 2009-03-16 CY CY20091100288T patent/CY1108883T1/el unknown
- 2009-11-05 HK HK09110323.8A patent/HK1132653A1/xx unknown
-
2010
- 2010-05-06 NO NO20100656A patent/NO332559B1/no not_active IP Right Cessation
- 2010-10-06 JP JP2010226970A patent/JP5273746B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-13 BE BE2013C029C patent/BE2013C029I2/fr unknown
- 2013-05-13 CY CY2013019C patent/CY2013019I1/el unknown
- 2013-05-14 LU LU92195C patent/LU92195I2/fr unknown
- 2013-05-14 LT LTPA2013009C patent/LTC1183353I2/lt unknown
- 2013-05-14 FR FR13C0028C patent/FR13C0028I2/fr active Active
- 2013-05-15 NO NO2013010C patent/NO2013010I1/no unknown
- 2013-09-17 HU HUS1300052C patent/HUS1300052I1/hu unknown
- 2013-11-26 HK HK13113191.5A patent/HK1185798A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP3208A (xx) | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama | |
MXPA03006806A (es) | Metodo para usar variante del receptor del factor de crecimiento celular endotelial vascular para tratar psoriasis y para mejorar curacion de heridas. | |
IL144654A0 (en) | Pancreatic progenitor cells, methods and uses related thereto | |
MXPA02000012A (es) | Polipeptidos hibridos con propiedades farmacocineticas mejoradas. | |
AU2001291687A1 (en) | Polyammonium-polysiloxane compounds, methods for the production and use thereof | |
HK1045311A1 (en) | Triazole compounds with dopamine-d3-receptor affinity | |
IL146482A (en) | Tek antagonists | |
MY120601A (en) | C-21 modified epothilones | |
NO20001408L (no) | Smal MWD, optimalisert etylen interpolymerblanding, fremgangsmÕte for fremstilling derav og gjenstander fremstilt derav | |
NO20010729D0 (no) | Fremgangsmåte for komplettering av löse, produserende soner i undergrunnen | |
WO2001000244A3 (fr) | Techniques de traitement utilisant des conjugues maytansinoides-anticorps anti-erbb | |
BG108494A (en) | Pulmonary administration of chemically modified insulin | |
GEP20105118B (en) | Anti-vegf antibodies | |
IL139702A0 (en) | Hylbrid polypeptides with enhanced pharmacokinetic properties | |
WO2001072657A3 (fr) | Composition de beton conducteur | |
EP1156820A4 (fr) | Facteur-2 de croissance endotheliale vasculaire | |
TWI317736B (en) | Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications | |
ZA200007771B (en) | Textile spun-dyed fiber material and use thereof for producing camouflage articles. | |
IL145018A0 (en) | Perfluoroalkylamide, the production thereof and the use thereof in diagnostics | |
GB9918011D0 (en) | 3-D sandwich preforms and method to provide the same | |
AU7937600A (en) | Wholly elastic knitted fabrics and methods of producing the same | |
DK1065277T3 (da) | Alfa-amylasemutanter | |
AU2580300A (en) | Cloth for sportswear, use of said cloth in producing sportswear, and also said sportswear | |
CU23070A3 (es) | Reduccion de la capa fludizada de finos de laterita con reduccion de gases generados in situ. | |
ZA200103695B (en) | Process for the manufacture in pure form of 1-pentene or alpha-olefin lower than 1-pentene. |